1. Home
  2. ABUS vs WDI Comparison

ABUS vs WDI Comparison

Compare ABUS & WDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.73

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Logo Western Asset Diversified Income Fund of Beneficial Interest

WDI

Western Asset Diversified Income Fund of Beneficial Interest

HOLD

Current Price

$13.66

Market Cap

699.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABUS
WDI
Founded
2005
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
839.5M
699.3M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
ABUS
WDI
Price
$4.73
$13.66
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
2.3M
190.1K
Earning Date
05-14-2026
01-01-0001
Dividend Yield
N/A
11.80%
EPS Growth
55.26
N/A
EPS
0.87
1.12
Revenue
$14,083,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$239.71
N/A
P/E Ratio
$5.52
$12.11
Revenue Growth
128.21
N/A
52 Week Low
$3.08
$12.91
52 Week High
$5.10
$15.28

Technical Indicators

Market Signals
Indicator
ABUS
WDI
Relative Strength Index (RSI) 64.91 61.53
Support Level $4.15 $13.60
Resistance Level $4.85 $13.79
Average True Range (ATR) 0.18 0.19
MACD 0.05 0.04
Stochastic Oscillator 85.54 86.36

Price Performance

Historical Comparison
ABUS
WDI

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About WDI Western Asset Diversified Income Fund of Beneficial Interest

Western Asset Diversified Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income. As a secondary investment objective, the Fund will seek capital appreciation. The fund seeks to achieve its investment objectives by investing, under normal market conditions, across fixed income sectors and securities in seeking to deliver a well-diversified portfolio.

Share on Social Networks: